ARTICLE | Clinical News
Interleukin-2: Started two Phase III trials with partner Eli Lilly, enrolling 120 and 64 patients, respectively. Each trial will test two doses, 9 and 18 µg/kg
March 20, 1995 8:00 AM UTC
Seragen Inc. (SRGN), Hopkinton, Mass. Product: Interleukin-2 (IL-2)-targeted fusion toxin with diphtheria toxin Indication: Cutaneous T cell lymphoma Status: Started two Phase III trials with partner ...